Difference between revisions of "Estramustine"

Estramustine
	File:Estramustine Structural Formulae.png
	File:Estramustine-3D-vdW.png
Systematic (IUPAC) name
	(17β)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate
Pharmacokinetic data
Biological half-life	20 hours
Identifiers
CAS Number	2998-57-4
ATC code	L01XX11 (WHO)
PubChem	CID 18140
DrugBank	APRD00625
Chemical data
Formula	C23H31Cl2NO3
Molar mass	440.403 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".
(verify)

Latest revision as of 10:00, 20 September 2010

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Estramustine (Emcyt, Estracit) is a chemotherapy agent used to treat prostate cancer. It is a derivative of estrogen (specifically, estradiol) with a nitrogen mustard-carbamate ester moiety that makes it a alkylating antineoplastic agent similar to mechlorethamine, with estrogen-induced specificity.

Estramustine is marketed in the United States by Pharmacia (now a subsidiary of Pfizer)

Estramustine is indicated for the palliative treatment of metastatic and/or progressive carcinoma of the prostate.

Fex, H. J.; Hogberg, K. B.; Konyves, I.; Kneip, O. J.; 1967, U.S. Patent 3,299,104.

Revision as of 19:37, 19 June 2010 (view source) Luckas-bot (Talk) m (robot Adding: es:Estramustina)	Latest revision as of 10:00, 20 September 2010 (view source) Jontas (Talk \| contribs) m (1 revision)
(No difference)